Your browser doesn't support javascript.
loading
Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations.
Akhtar, Marjahan; Islam, Md Rashedul; Khaton, Fatema; Soltana, Umma Hany; Jafrin, Syeda Anoushka; Rahman, Sadia Isfat Ara; Tauheed, Imam; Ahmed, Tasnuva; Khan, Ishtiakul Islam; Akter, Afroza; Khan, Zahid Hasan; Islam, Md Taufiqul; Khanam, Farhana; Biswas, Prasanta Kumar; Ahmmed, Faisal; Ahmed, Shakeel; Rashid, Md Mamunur; Hossain, Md Zakir; Alam, Ahmed Nawsher; Alamgir, A S M; Rahman, Mahbubur; Ryan, Edward T; Harris, Jason B; LaRocque, Regina C; Flora, Meerjady Sabrina; Chowdhury, Fahima; Khan, Ashraful Islam; Banu, Sayera; Shirin, Tahmina; Bhuiyan, Taufiqur Rahman; Qadri, Firdausi.
Affiliation
  • Akhtar M; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Islam MR; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Khaton F; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Soltana UH; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Jafrin SA; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Rahman SIA; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Tauheed I; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Ahmed T; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Khan II; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Akter A; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Khan ZH; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Islam MT; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Khanam F; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Biswas PK; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Ahmmed F; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Ahmed S; Bangladesh Institute of Tropical & Infectious Diseases, Chittagong, Bangladesh.
  • Rashid MM; Bangladesh Institute of Tropical & Infectious Diseases, Chittagong, Bangladesh.
  • Hossain MZ; Bangladesh Institute of Tropical & Infectious Diseases, Chittagong, Bangladesh.
  • Alam AN; Institute of Epidemiology, Disease Control and Research (IEDCR), Dhaka, Bangladesh.
  • Alamgir ASM; Institute of Epidemiology, Disease Control and Research (IEDCR), Dhaka, Bangladesh.
  • Rahman M; Institute of Epidemiology, Disease Control and Research (IEDCR), Dhaka, Bangladesh.
  • Ryan ET; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States.
  • Harris JB; Department of Medicine, Harvard Medical School, Boston, MA, United States.
  • LaRocque RC; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
  • Flora MS; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States.
  • Chowdhury F; Department of Pediatrics, Harvard Medical School, Boston, MA, United States.
  • Khan AI; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States.
  • Banu S; Department of Medicine, Harvard Medical School, Boston, MA, United States.
  • Shirin T; Directorate General of Health Services, Dhaka, Bangladesh.
  • Bhuiyan TR; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
  • Qadri F; Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
Front Immunol ; 14: 1309997, 2023.
Article in En | MEDLINE | ID: mdl-38173725
ABSTRACT

Background:

Understanding the characteristics of the humoral immune responses following COVID-19 vaccinations is crucial for refining vaccination strategies and predicting immune responses to emerging SARS-CoV-2 variants.

Methods:

A longitudinal analysis of SARS-CoV-2 spike receptor binding domain (RBD) specific IgG antibody responses, encompassing IgG subclasses IgG1, IgG2, IgG3, and IgG4 was performed. Participants received four mRNA vaccine doses (group 1; n=10) or two ChAdOx1 nCoV-19 and two mRNA booster doses (group 2; n=19) in Bangladesh over two years.

Results:

Findings demonstrate robust IgG responses after primary Covishield or mRNA doses; declining to baseline within six months. First mRNA booster restored and surpassed primary IgG responses but waned after six months. Surprisingly, a second mRNA booster did not increase IgG levels further. Comprehensive IgG subclass analysis showed primary Covishield/mRNA vaccination generated predominantly IgG1 responses with limited IgG2/IgG3, Remarkably, IgG4 responses exhibited a distinct pattern. IgG4 remained undetectable initially but increased extensively six months after the second mRNA dose, eventually replacing IgG1 after the 3rd/4th mRNA doses. Conversely, initial Covishield recipients lack IgG4, surged post-second mRNA booster. Notably, mRNA-vaccinated individuals displayed earlier, robust IgG4 levels post first mRNA booster versus Covishield counterparts. IgG1 to IgG4 ratios decreased with increasing doses, most pronounced with four mRNA doses. This study highlights IgG response kinetics, influenced by vaccine type and doses, impacting immunological tolerance and IgG4 induction, shaping future vaccination strategies.

Conclusions:

This study highlights the dynamics of IgG responses dependent on vaccine type and number of doses, leading to immunological tolerance and IgG4 induction, and shaping future vaccination strategies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin G / COVID-19 Type of study: Prognostic_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin G / COVID-19 Type of study: Prognostic_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Country of publication: